PMID-39444618 – DSIP Fusion Peptide BBB Crossing Insomnia Models
Mu X, et al. An engineered DSIP fusion peptide with enhanced blood-brain barrier penetration for insomnia treatment. Front Pharmacol. 2024;15:1439990.
Quick Reference
| Property | Value |
|---|---|
| PMID | 39444618 |
| DOI | 10.3389/fphar.2024.1439990 |
| Year | 2024 |
| Journal | Frontiers in Pharmacology |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | PCPA-induced insomnia mouse model |
| Peptide(s) Studied | DSIP |
Key Findings
- An engineered DSIP fusion peptide was designed with enhanced blood-brain barrier (BBB) penetration compared to native DSIP
- The fusion peptide successfully crossed the BBB in vivo, achieving higher CNS concentrations than unmodified DSIP
- In PCPA (para-chlorophenylalanine)-induced insomnia mice, the fusion peptide restored sleep parameters toward normal, including increased total sleep time and improved sleep architecture
- PCPA depletes serotonin, creating a pharmacologically induced insomnia model; DSIP's efficacy in this model suggests activity independent of or complementary to serotonergic pathways
- The engineering approach preserved DSIP's biological activity while improving its pharmacokinetic profile for CNS delivery
- Sleep restoration was assessed by EEG/EMG monitoring, demonstrating objective improvements in sleep continuity and delta power
Study Design
Preclinical pharmacology study combining peptide engineering with in vivo efficacy testing. A DSIP fusion peptide was designed and synthesized with a BBB-penetrating moiety. BBB crossing was validated using in vivo brain distribution studies. Insomnia was modeled in mice using PCPA (serotonin synthesis inhibitor). Sleep was assessed by implanted EEG/EMG electrodes. Treated animals were compared to vehicle controls and native DSIP.
Limitations
- Animal model; PCPA-induced insomnia is a pharmacological model that does not replicate the complexity of human insomnia
- The engineered fusion peptide is a novel construct, not commercially available DSIP
- Limited characterization of potential off-target effects of the fusion moiety
- Single insomnia model tested; efficacy in other insomnia subtypes unknown
- Short-term study; chronic dosing effects not assessed
Clinical Relevance
This 2024 study represents the most modern approach to DSIP therapeutics, addressing the long-standing challenge of BBB penetration that has limited DSIP's clinical development. The successful sleep restoration in an insomnia model validates DSIP's continued relevance as a sleep-promoting peptide. For current clinical practice, while this specific fusion peptide is not available, the findings reinforce that DSIP has genuine sleep-promoting activity when adequate CNS concentrations are achieved — supporting the rationale for subcutaneous administration which may achieve better CNS exposure than oral delivery.
Related
#research #animal-in-vivo #evidence-level-V